The Impact of Inverted Duty on Pharma MSMEs
The Pharmaceutical Export Promotion Council of India (Pharmexcil) has formally initiated a sector-wide consultation process to address the mounting financial strain on Micro, Small, and Medium Enterprises (MSMEs) caused by an inverted duty structure. As of late 2023 and early 2024, small-scale drug manufacturers have reported that the tax paid on inputs is higher than the tax on their finished pharmaceutical products, leading to a persistent accumulation of unutilized input tax credits. Pharmexcil is currently gathering data from its member base to submit a comprehensive representation to the Ministry of Commerce and Industry, aiming to rectify these structural imbalances.
Contextualizing the GST 2.0 Shift
The issue stems from the broader implementation of GST 2.0, which sought to streamline tax compliance but inadvertently disrupted the cost-efficiency of smaller manufacturing units. Under the current tax framework, pharmaceutical raw materials, such as Active Pharmaceutical Ingredients (APIs) and specialized excipients, often attract a higher GST rate than the final medicinal formulations. This inversion prevents MSMEs from effectively claiming refunds for the excess input taxes paid, effectively locking up their working capital.
Detailed Coverage of Industry Challenges
For many small-scale manufacturers, the inability to claim these credits has created a liquidity crunch that hinders production capacity and export competitiveness. Industry analysts suggest that while large pharmaceutical corporations possess the legal and financial resources to navigate these tax complexities, MSMEs are disproportionately affected due to limited cash reserves. The administrative burden of tracking these credits has also increased the cost of compliance for smaller firms, further eroding their profit margins in an already price-sensitive market.
Expert Perspectives and Economic Data
Trade experts highlight that the pharmaceutical sector serves as a critical pillar of the national economy, contributing significantly to global drug supplies. According to recent feedback provided to Pharmexcil, member companies have expressed that the current tax structure acts as a disincentive for domestic production. Data indicates that if the inverted duty is not corrected, the growth rate of MSMEs—which account for a significant portion of the domestic drug manufacturing workforce—could see a sharp decline in the coming fiscal quarters.
Implications for the Pharmaceutical Sector
The primary implication of this ongoing tax issue is a potential reduction in the availability of affordable generic medicines, as manufacturers struggle to absorb the hidden costs. If the Ministry decides to implement a corrective policy, it would likely involve a recalibration of GST slabs for specific drug inputs to ensure parity with finished goods. Industry stakeholders are watching closely to see if the government will offer relief, such as an expedited refund mechanism or a restructuring of tax rates, to stabilize the sector.
Future Outlook and Monitoring
Moving forward, the industry is closely monitoring the upcoming federal budget discussions and GST Council meetings for signs of relief. Pharmexcil’s forthcoming submission is expected to set the agenda for future negotiations with the government. Observers should look for potential policy shifts that prioritize input tax credit liquidity for MSMEs, as this will determine the long-term viability of small-scale pharmaceutical innovation and domestic supply chain resilience.
